#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #LOTIS-5

ADC Therapeutics Implements Strategic Reorganization for ZYNLONTA

ADC Therapeutics SA, a prominent player in the antibody drug conjugates (ADCs) sector, recently announced a strategic reorganization aimed at bolstering its leading product, ZYNLONTA® (loncastuximab tesirine-lpyl). The company plans to reduce its global workforce by about 17%, a move projected to generate substantial cost savings and improve its financial agility.

The reorganization comes in light of the expected completion of pivotal Phase 3 clinical trials, specifically the LOTIS-5 and LOTIS-7 studies, which are critical to ZYNLONTA's regulatory approval process. By reallocating resources towards high-impact initiatives, ADC Therapeutics intends to enhance its capacity for regulatory submissions and the advancement of clinical trials.

CEO Ameet Mallik expressed confidence in ZYNLONTA’s favorable risk-benefit profile, citing positive feedback from key medical experts regarding the LOTIS-5 trial. The company is gearing up for a pre-supplemental Biologics License Application (sBLA) meeting with the FDA, scheduled for August 2026. This meeting will address ZYNLONTA's regulatory pathway in combination with rituximab as a treatment for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

ADC Therapeutics has ambitious plans for ZYNLONTA, anticipating the submission of the sBLA by the end of Q4 2026, which would significantly impact the treatment landscape for DLBCL patients.

Cost Reduction and Future Prospects

The reorganization is not solely focused on workforce reduction; it is designed to optimize operational efficiencies within the company. ADC Therapeutics estimates that this restructuring will culminate in annualized savings of approximately $10 million. However, the company anticipates incurring one-time charges of around $3 million related to severance and employee benefits. Most of these costs will be recognized in the second quarter of 2026.

With these cost-saving measures, ADC Therapeutics aims to maintain a robust operational structure capable of supporting its remaining medical affairs and commercial activities. The strategic decision reflects the company’s commitment to deliver meaningful advancements in patient care through innovative therapies.

The ZYNLONTA Advantage

ZYNLONTA is an FDA and EMA-approved ADC specifically targeting CD19, a marker commonly found on B-cell malignancies. It works by delivering a potent payload that binds to the DNA of cancer cells, causing cell cycle arrest and promoting tumor cell death. This revolutionary treatment is crucial for adult patients with r/r DLBCL, especially those who have undergone multiple lines of therapy and continue to seek effective options.

The company is also exploring ZYNLONTA in combination trials for various B-cell malignancies and earlier lines of therapy, enhancing its therapeutic potential and adaptability.

Looking Ahead

As ADC Therapeutics navigates this transformative phase, the organization remains focused on its regulatory and clinical milestones. The completion of the LOTIS-5 and LOTIS-7 trials is expected to provide significant data to substantiate the efficacy of ZYNLONTA and its future in treating challenging B-cell hematologic malignancies.

This restructuring aims to streamline operations while gearing up for an exciting regulatory path forward, reflecting ADC Therapeutics’ dedication to innovation and patient-centric care in the evolving landscape of oncology treatment.